Etoricoxib

This classification denotes a cyclooxygenase inhibitor with the molecular formula C18H15ClN2O2S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier WRX4NFY03R, chemically known as 2,3-bipyridine, 5-chloro-6-methyl-3-(4-(methylsulfonyl)phenyl)- but generally known as etoricoxib, which bears US NIH Compound Identifier 123619. European Medicines Agency schedules Etoricoxib in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB16429MIG. The term ETORICOXIB is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 15 No. 3-4, 2001, List 46). World Health Organization schedules etoricoxib in its Anatomical Therapeutic Chemical (ATC) Classification. Most nations schedule etoricoxib under HS 29333999 and SITC 51574. As of Q4 2014, ETORICOXIB remains the US FDA Preferred Term for this commodity. Etoricoxib bears US NLM identifiers UMLS ID C0972314 and NCI Concept Code C52188. SMILES: CLC1CC(C2CCC(S(=O)(=O)C)CC2)C(NC1)C1CCC(NC1)C.